Precision BioSciences (NASDAQ:DTIL) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Precision BioSciences (NASDAQ:DTIL) issued its quarterly earnings data on Tuesday. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.09), FiscalAI reports. The company had revenue of $10.84 million during the quarter, compared to the consensus estimate of $4.05 million. Precision BioSciences had a negative net margin of 133.45% and a negative return on equity of 122.60%.

Precision BioSciences Trading Up 4.8%

Shares of Precision BioSciences stock opened at $7.63 on Tuesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 13.32 and a current ratio of 13.32. The firm has a 50-day moving average of $6.02 and a 200-day moving average of $5.36. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $8.82. The stock has a market cap of $196.85 million, a PE ratio of -1.49 and a beta of 1.31.

Analyst Upgrades and Downgrades

DTIL has been the topic of a number of research reports. Wall Street Zen upgraded shares of Precision BioSciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Jefferies Financial Group restated a “buy” rating and set a $19.00 price objective on shares of Precision BioSciences in a report on Friday, March 13th. Finally, JonesTrading reaffirmed a “buy” rating and issued a $30.00 target price on shares of Precision BioSciences in a research report on Friday, April 17th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Precision BioSciences presently has an average rating of “Moderate Buy” and an average target price of $36.33.

Insider Transactions at Precision BioSciences

In other Precision BioSciences news, CEO Michael Amoroso sold 20,559 shares of Precision BioSciences stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total value of $78,946.56. Following the completion of the sale, the chief executive officer owned 243,392 shares in the company, valued at $934,625.28. The trade was a 7.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO John Alexander Kelly sold 8,149 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total transaction of $31,292.16. Following the completion of the sale, the chief financial officer directly owned 125,883 shares of the company’s stock, valued at $483,390.72. This represents a 6.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 33,633 shares of company stock worth $129,151. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Precision BioSciences

A number of large investors have recently added to or reduced their stakes in DTIL. Geode Capital Management LLC increased its stake in Precision BioSciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after acquiring an additional 4,025 shares during the period. Bridgeway Capital Management LLC bought a new stake in shares of Precision BioSciences during the 2nd quarter valued at $260,000. Corient Private Wealth LLC acquired a new stake in shares of Precision BioSciences during the 2nd quarter worth $425,000. Vanguard Group Inc. grew its holdings in shares of Precision BioSciences by 21.5% during the 3rd quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock worth $2,719,000 after purchasing an additional 87,242 shares in the last quarter. Finally, Lynx1 Capital Management LP increased its position in shares of Precision BioSciences by 0.6% in the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after purchasing an additional 6,545 shares during the period. Institutional investors and hedge funds own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.